102 related articles for article (PubMed ID: 3376191)
1. [Interindividual variability in drug metabolism, especially in the elderly. Underlying mechanisms and a possible solution].
van Bezooijen CF
Tijdschr Gerontol Geriatr; 1988 Apr; 19(2):61-4. PubMed ID: 3376191
[TBL] [Abstract][Full Text] [Related]
2. The influence of dietary restriction on the metabolism of theophylline and antipyrine in the ageing female BN/BiRij rat.
Groen K; Breimer DD; Brouwer A; Schijff G; Jansen EJ; van Bezooijen CF
J Pharmacol Exp Ther; 1995 Jul; 274(1):143-7. PubMed ID: 7616391
[TBL] [Abstract][Full Text] [Related]
3. Correlation between antipyrine metabolite formation and theophylline metabolism in humans after simultaneous single-dose administration and at steady state.
Teunissen MW; De Leede LG; Boeijinga JK; Breimer DD
J Pharmacol Exp Ther; 1985 Jun; 233(3):770-5. PubMed ID: 4009489
[TBL] [Abstract][Full Text] [Related]
4. Relationship between metabolic clearance rate of antipyrine and hepatic microsomal drug-oxidizing enzyme activities in humans without liver disease.
Vuitton D; Miguet JP; Camelot G; Delafin C; Joanne C; Bechtel P; Gillet M; Carayon P
Gastroenterology; 1981 Jan; 80(1):112-8. PubMed ID: 7450397
[TBL] [Abstract][Full Text] [Related]
5. The effect of age on antipyrine pharmacokinetics and metabolite formation in rats.
van Bezooijen CF; van Oorschot RM
J Pharmacol Exp Ther; 1989 Nov; 251(2):683-6. PubMed ID: 2810117
[TBL] [Abstract][Full Text] [Related]
6. Antipyrine as a probe for human oxidative drug metabolism: identification of the cytochrome P450 enzymes catalyzing 4-hydroxyantipyrine, 3-hydroxymethylantipyrine, and norantipyrine formation.
Engel G; Hofmann U; Heidemann H; Cosme J; Eichelbaum M
Clin Pharmacol Ther; 1996 Jun; 59(6):613-23. PubMed ID: 8681486
[TBL] [Abstract][Full Text] [Related]
7. Drug metabolism and drug interactions in the elderly.
Herrlinger C; Klotz U
Best Pract Res Clin Gastroenterol; 2001 Dec; 15(6):897-918. PubMed ID: 11866484
[TBL] [Abstract][Full Text] [Related]
8. Hepatocytes--the choice to investigate drug metabolism and toxicity in man: in vitro variability as a reflection of in vivo.
Gómez-Lechón MJ; Castell JV; Donato MT
Chem Biol Interact; 2007 May; 168(1):30-50. PubMed ID: 17134688
[TBL] [Abstract][Full Text] [Related]
9. The influence of aging on the metabolism of simultaneously administered hexobarbital enantiomers and antipyrine before and after phenobarbital induction in male rats: a longitudinal study.
Groen K; Breimer DD; Jansen EJ; van Bezooijen CF
J Pharmacol Exp Ther; 1994 Feb; 268(2):531-6. PubMed ID: 8113964
[TBL] [Abstract][Full Text] [Related]
10. Effects of model traumatic injury on hepatic drug metabolism in the rat. III. Differential responses of cytochrome P-450 subpopulations.
Griffeth LK; Rosen GM; Rauckman EJ
Drug Metab Dispos; 1984; 12(5):588-95. PubMed ID: 6149909
[TBL] [Abstract][Full Text] [Related]
11. Correlation between the in vivo metabolism of hexobarbital and antipyrine in rats.
van der Graaff M; Vermeulen NP; Joeres RP; Vlietstra T; Breimer DD
J Pharmacol Exp Ther; 1983 Nov; 227(2):459-65. PubMed ID: 6631725
[TBL] [Abstract][Full Text] [Related]
12. Effects of water deprivation on drug pharmacokinetics: correlation between drug metabolism and hepatic CYP isozymes.
Lee JH; Oh JM; Lee MG
Arch Pharm Res; 2008 Aug; 31(8):951-64. PubMed ID: 18787780
[TBL] [Abstract][Full Text] [Related]
13. Polymorphism of human cytochrome P450 enzymes and its clinical impact.
Zhou SF; Liu JP; Chowbay B
Drug Metab Rev; 2009; 41(2):89-295. PubMed ID: 19514967
[TBL] [Abstract][Full Text] [Related]
14. A simple non-invasive procedure for the investigation of cytochrome P-450 IIIA dependent enzymes in humans.
Bienvenu T; Rey E; Pons G; d'Athis P; Olive G
Int J Clin Pharmacol Ther Toxicol; 1991 Nov; 29(11):441-5. PubMed ID: 1800391
[TBL] [Abstract][Full Text] [Related]
15. Identification of the human hepatic cytochromes P450 involved in the in vitro oxidation of antipyrine.
Sharer JE; Wrighton SA
Drug Metab Dispos; 1996 Apr; 24(4):487-94. PubMed ID: 8801065
[TBL] [Abstract][Full Text] [Related]
16. The current state of knowledge on age, sex, and their interactions on clinical pharmacology.
Schwartz JB
Clin Pharmacol Ther; 2007 Jul; 82(1):87-96. PubMed ID: 17495875
[TBL] [Abstract][Full Text] [Related]
17. Bioequivalence revisited: influence of age and sex on CYP enzymes.
Bebia Z; Buch SC; Wilson JW; Frye RF; Romkes M; Cecchetti A; Chaves-Gnecco D; Branch RA
Clin Pharmacol Ther; 2004 Dec; 76(6):618-27. PubMed ID: 15592333
[TBL] [Abstract][Full Text] [Related]
18. Interindividual differences in rates of drug oxidation in man.
Davies DS; Thorgeirsson SS; Breckenridge A; Orme M
Drug Metab Dispos; 1973; 1(1):411-7. PubMed ID: 4149412
[No Abstract] [Full Text] [Related]
19. [Features of the metabolism of various drugs involving cytochrome P-450 isoenzymes].
Filimonova AA; Ziganshin AU; Ziganshina LE
Eksp Klin Farmakol; 2007; 70(3):69-77. PubMed ID: 17650639
[TBL] [Abstract][Full Text] [Related]
20. The effect of age, sex, and rifampin administration on intestinal and hepatic cytochrome P450 3A activity.
Gorski JC; Vannaprasaht S; Hamman MA; Ambrosius WT; Bruce MA; Haehner-Daniels B; Hall SD
Clin Pharmacol Ther; 2003 Sep; 74(3):275-87. PubMed ID: 12966371
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
